Oliver Wyman March 14, 2024
Tobias Handschuh and Matthew Lakelin

Since the infrastructure needed to support cell and gene therapies is so complex, companies must assess supply chain issues early, even before entering human studies.

Begin with the end in mind. That’s Matthew Lakelin’s advice for companies aiming to bring cell and gene therapies to market.

Because the infrastructure needed to support cell and gene therapies is so complex, companies must consider supply chain issues very early on, even before they enter human studies, said Lakelin, Vice President of Scientific Affairs at TrakCel, a company that helps manage all components of the cell and gene therapy supply chain.

For instance, blood,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech, Supply Chain, Technology
How has U.S. Spending on Health Care Changed Over Time?
Merck enters $2B licensing deal for weight loss drug
How Medicare Negotiated Drug Prices Compare to Other Countries
The Fed's Warnings On Inflation Are Bad News For Biotech Startups
AI Tech Firm SandboxAQ Adds $300M to Ramp Up Development of LQMs for Drug Discovery & More

Share This Article